Caplin Point Laboratories announced strong Q3FY26 results, with total revenue reaching ₹1,674 Crores, an 11.2% year-over-year increase. Q3FY26 revenue stood at ₹577 Crores, demonstrating a 10% sequential increase. The company reported a ₹477 Crores PAT for 9MFY26, a 20.5% year-over-year growth, and noted US market revenue of ₹335 Crores, a 25% increase year-over-year. Free cash reserves are at ₹1,381 Crores, and liquid assets at ₹2,459 Crores.
Financial Performance Highlights
Caplin Point Laboratories reported the following consolidated financial results:
- Revenue from Operations (9MFY26): ₹1,587.0 Crores, up 10.6% YoY
- Total Revenue (9MFY26): ₹1,674.2 Crores, up 11.2% YoY
- Gross Profit (9MFY26): ₹966.4 Crores, up 11.7% YoY
- EBITDA (9MFY26): ₹643.8 Crores, up 17.1% YoY
- Profit Before Tax (9MFY26): ₹589.4 Crores, up 17.8% YoY
- Profit After Tax (9MFY26): ₹476.9 Crores, up 20.5% YoY
The company’s Gross Margin for 9MFY26 is 60.9%, and EBITDA Margin for 9MFY26 is 38.5%.
Segmental Performance
The company has two reportable segments:
- Rest of the World: Segment revenue stood at ₹1,263.54 Crores for 9MFY26.
- United States of America (USA): Segment revenue stood at ₹323.49 Crores for 9MFY26.
Strategic Growth Initiatives
Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for investment projects. These projects aim to augment existing production capacities, broaden the product range and achieve backward integration for most products. Key projects include:
- CP1, Suthukeny, Puducherry: Lyophilized Injectables and Dual Chamber Syringes (Completed).
- Visakhapatnam, Andhra Pradesh: General API (Completed).
- SIDCO, Kakkalur (Near Chennai): OSD & Injectable phase (Completed).
- Thervoy SIPCOT, Chennai: Oncology API (Targeted completion in Q3 FY27).
- Puducherry: Oral Solid Dosages (Targeted completion in Q3 FY27).
- Gummidipoondi, Chennai: Injectables and Opthalmics (Targeted completion in Q4 FY27).
Key Business Updates
- The company is increasing its focus on Oncology and API manufacturing.
- Caplin Steriles Limited (CSL) continues to show strong growth in the US market.
- The company received EU GMP renewal certification.
Source: BSE
